BridgeMD
New treatment option for Smell Dysfunction
Official title Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
ClinicalTrials.gov ID: NCT05855369
What this study is testing
- What it's testing
- Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- treatment-seeking for COVID-related persistent SL (anosmia, hyposmia, phantosmia or parosmia)
- at least 1-month from SARS-coV-2 PCR-positive and/or rapid home-positive tests
- normal sense of smell prior to COVID
- naïve to both smell training (ST) and trigeminal nerve stimulation (TNS)
- able to comprehend English and provide informed consent
You likely can't join if
- history of head injury (e.g. sport, accident, combat blast)
- sinonasal condition (e.g. upper respiratory infection, rhinosinusitis, polyps)
- neurological disorder (e.g. epilepsy, neurodegenerative disorder, narcolepsy)
- serious mental illness (e.g. schizophrenia, bipolar, or other psychotic disorder)
- suicidal ideation within the last month
- current (≤6 months) heavy cigarette smoker (heavy defined as ≥ 10 pack-years)
See the full eligibility criteria
- treatment-seeking for COVID-related persistent SL (anosmia, hyposmia, phantosmia or parosmia)
- at least 1-month from SARS-coV-2 PCR-positive and/or rapid home-positive tests
- normal sense of smell prior to COVID
- naïve to both smell training (ST) and trigeminal nerve stimulation (TNS)
- able to comprehend English and provide informed consent
- history of head injury (e.g. sport, accident, combat blast)
- sinonasal condition (e.g. upper respiratory infection, rhinosinusitis, polyps)
- neurological disorder (e.g. epilepsy, neurodegenerative disorder, narcolepsy)
- serious mental illness (e.g. schizophrenia, bipolar, or other psychotic disorder)
- suicidal ideation within the last month
- current (≤6 months) heavy cigarette smoker (heavy defined as ≥ 10 pack-years)
- oral/nasal steroids or other intranasal medications within the last month
- immunomodulatory medications
- pregnant or trying to become pregnant
The study team makes the final eligibility decision.
Where it's taking place
- Charleston, South Carolina, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Charleston, South Carolina, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.